Casdatifan

Casdatifan (AB521) is an orally active HIF-2α (hypoxia-inducible factor 2α) inhibitor. Casdatifan exhibited significant antitumor activity and favorable pharmacokinetics in ccRCC (clear cell renal cell carcinoma) models[1].

Product Specifications

CAS Number

[2709069-30-5]

Product Name Alternative

AB521

UNSPSC

12352005

Target

HIF/HIF Prolyl-Hydroxylase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/casdatifan.html

Purity

96.37

Smiles

CS(C(C1=C2C[C@@H](F)[C@H]1O)=CC=C2[C@](C[C@H](F)[C@@H]3F)([H])C4=C3C=C(F)C=C4C#N)(=O)=O

Molecular Formula

C21H17F4NO3S

Molecular Weight

439.42

References & Citations

[1]Patrick G Schweickert, et al. Casdatifan (AB521) is a novel and potent allosteric small molecule inhibitor of protumourigenic HIF-2α dependent transcription. Br J Pharmacol. 2025 Sep;182 (17) :4147-4167.